Mar 18, 2008
Lev Presents Results of Phase III Study Supporting Safety and...
“Patients with hereditary angioedema live with the constant threat of severe and potentially life-threatening angioedema attacks”
Lev Presents Results of Phase III Study Supporting Safety and Efficacy of Cinryze as Prophylactic Therapy for HAE PHILADELPHIA & NEW YORK-- --Mar 18, 2008 - Lev Pharmaceuticals, Inc. via Med Ad News
Comments
Please note by clicking on "Post Comment" you acknowledge that you have read the Terms of Service and the comment you are posting is in compliance with such terms. Be polite. Inappropriate posts may be removed by the moderator. Send us your feedback.
| Topic | Updated | Last By | Comments |
|---|---|---|---|
| Angioedema. Please comment. | Jul 17 | Peter | 2 |
| New to all this (from Apr '06) | Apr '06 | Anita | 1 |

